Freeze and burn: new device targets lung cancer during bronchoscopy
NCT ID NCT07398027
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a device called the HybridTherm® system, which uses freezing and radiofrequency heat to destroy small lung tumors during a routine bronchoscopy. The procedure is done before the patient's planned surgery to remove the tumor. The main goals are to see if the device works as intended and to check for any serious bleeding. Only 20 people with early-stage lung cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HybridTherm® System (device that combines freezing and radiofrequency heat to destroy tumors)
- What this could lead to
- If successful, this could provide a less invasive way to treat small lung tumors, potentially reducing the need for more extensive surgery.
- What could go wrong
- This is a very early, small study (20 people) focused on feasibility, not effectiveness. The procedure carries risks like bleeding, and it's unknown if it will work better than current treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who require diagnostic bronchoscopy for suspicious lung lesions with mediastinal lymph node status confirmed as NO by one of the following: Prior PET-CT showing no FDG-avid mediastinal lymph nodes, OR intraoperative EBUS-TBNA with ROSE confirming negative lymph nodes (performed when clinically indicated per section 6.1). * Solitary pulmonary lesions ≤ 2.5cm with histologically or cytologically confirmed primary lung cancer. * Suitable candidate for surgical resection of the tumor targeted for ablation * Interdisciplinary tumor board consent * Ability to read, understand, and sign patient Informed Consent Form (ICF) * Age ≥ 18-years-old * ≥ 20 mm of free space between the calculated intended ablation zone and the lung parenchyma or any critical structures (pleura, vessels and main bronchi). Exclusion Criteria: * Pregnant or nursing (breast feeding) females * Central tumors abutting vital structures (main bronchus, pulmonary artery, esophagus, trachea) * Thoracic electronic implants (e.g., pacemakers, ICDs) * Uncorrectable coagulopathy or platelet count ≤ 50,000/mm³ * Patients receiving anticoagulant therapy or with pulmonary hypertension that, in the opinion of the Investigator, poses an unacceptable safety risk for bronchoscopy and ablation. * Severe, uncontrolled comorbidities * Active systemic infection * Prior radiation therapy (SBRT) in the intended ablation zone * Recent Investigational therapy within the last 30 days that the investigator deems could interfere with proceeding in the clinical investigation * Tumors associated with atelectasis, obstructive pneumonitis, pleural effusion, or fibrosis * Investigators determine that study participation poses safety risk * Any comorbidities judged by the principal Investigator to be contraindicated for bronchoscopy * Subject was judged unsuitable for study participation by the Investigator for any other reason
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital Zurich
Zurich, Raemistrasse, 8091, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Can AI make lung cancer scans easier to read?
- Two-Drug combo targets Treatment-Resistant lung cancer
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- App aims to catch a hidden radiotherapy side effect
- Which nerve block wins for lung surgery pain?